ATOSSA THERAPEUTICS, INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- ATOSSA THERAPEUTICS, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-09-30 was $1.32M.
- ATOSSA THERAPEUTICS, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-06-30 was $152.00K.
- ATOSSA THERAPEUTICS, INC. treasury stock, value, acquired, cost method for fiscal 2023 was $1.48M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2023-12-31 | $1.48M 10-K · filed 2025-03-25 | |
| 2023-09-30 | $1.32M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $152.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |